STAGE IV PANCREATIC CANCER AJCC V8

This study tests whether adding pembrolizumab (an immunotherapy) to olaparib (a targeted therapy) works better than olaparib alone for people with metastatic pancreatic cancer who have inherited BRCA1 or BRCA2 mutations. About 88 participants will receive either the combination o…

This study tests a combination of two targeted drugs, palbociclib and binimetinib, in people with cancers that have RAS mutations (like certain ovarian and pancreatic cancers). The goal is to see if the combo can slow tumor growth better than one drug alone. About 199 adults will…

This early-stage trial tests a new targeted drug (CA-4948) added to standard chemotherapy for people with advanced pancreatic cancer that has spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink or stabilize the cancer. About 43 ad…

This study tests whether a combination of two drugs, lenvatinib and pembrolizumab, can help keep advanced pancreatic cancer from getting worse in people whose cancer cannot be removed by surgery. About 28 adults who have already responded to initial treatment will receive these d…

This early-phase trial tests a combination of two drugs—calaspargase pegol-mknl and cobimetinib—in about 15 people with advanced pancreatic cancer that has spread. The goal is to find the safest dose and see how well the drugs work together to starve cancer cells by cutting off a…

This early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…

This early-phase trial tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The study combines a targeted therapy (anetumab ravtansine) with immunotherapy drugs (nivolumab, ipilimumab) and chemotherapy (gemcitabine) to s…

This early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 adults with cance…

This study compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combination (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer that has spread to other parts of the body. Participant…

This study tests a technique called sonoporation, which uses ultrasound and tiny bubbles to help chemotherapy drugs get into cancer cells more effectively. It includes 120 adults with advanced or hard-to-remove pancreatic cancer who are already scheduled for standard chemotherapy…

This study tests two different chemotherapy combinations in older adults (age 70+) whose pancreatic cancer has spread. The goal is to see which treatment helps people live longer. Both treatments are already used for pancreatic cancer, but this trial focuses specifically on older…

This study tests whether switching from one chemotherapy combination to another before surgery can help people with pancreatic cancer that can be removed or has spread nearby. About 42 adults with specific stages of pancreatic cancer will receive either FOLFIRINOX or gemcitabine/…

This early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…

This study tests whether a supervised, at-home resistance training program using a tablet is safe and helpful for people with advanced pancreatic cancer or those recovering from surgery. About 25 participants will do guided exercises while on chemotherapy or after surgery. The go…